CASI Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CASI research report →
About the company
CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma.
- CEO
- David A. Cory
- IPO
- 1996
- Employees
- 233
- HQ
- Beijing, MD, US
Price Chart
- Market Cap
- $2.33M
- P/E
- -0.05
- P/S
- 0.15
- P/B
- -0.08
- EV/EBITDA
- -0.59
- Div Yield
- 0.00%
- Gross Margin
- 48.65%
- Op Margin
- -211.64%
- Net Margin
- -232.00%
- ROE
- 203.92%
- ROIC
- -2164.69%
- Revenue
- $28.54M · -15.77%
- Net Income
- $-39,258,000 · -45.73%
- EPS
- $-2.56 · -26.73%
- Op Income
- $-39,621,000
- FCF YoY
- -32.67%
- 52W High
- $3.09
- 52W Low
- $0.14
- 50D MA
- $0.86
- 200D MA
- $1.44
- Beta
- 0.89
- Avg Volume
- 225.20K
Get TickerSpark's AI analysis on CASI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Huang James | other | 0 |
| Mar 18, 26 | Huang James | other | 10,000 |
| Mar 18, 26 | Huang James | other | 10,000 |
| Mar 18, 26 | Huang James | other | 101,571 |
Our CASI coverage
Recent articles, reports, and earnings notes.
No research on CASI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CASI report →Similar companies
Peers in the same neighborhood.